• About us
• Contact

Advertisement

Organisation › Details

Bellevue (Group)

Bellevue Group is an independent Swiss financial boutique listed on the SIX Swiss Exchange. Established in 1993, the company and its approximately 80 employees are specialists in the fields of Brokerage, Corporate Finance and Asset Management. Bellevue Group includes the two subsidiaries Bank am Bellevue and Bellevue Asset Management. The bank boasts superb knowledge of the Swiss stock and bond market and offers independent research opinions and recommendations as well as viable solutions for capital market transactions. Bellevue Asset Management is focused on selected active equity investment strategies in growing markets, in healthcare industries as well as in other special themes such as entrepreneur-led companies. *

 

	Start	1993-01-01 established
	Industry	finance
	Industry 2	fund
	Person	Baumann, Urs (Bellevue Group 201409 CEO)
	Person 2	Rüegg, André (Bellevue Group 201409 CEO of Bellevue Asset Management)
	Region	Küsnacht ZH
	Country	Switzerland
	Street	16 Seestr.
	City	8700 Küsnacht ZH
	Tel	+41-1-267-6700
		Address record changed: 2020-12-02
Basic data	Employees	C: 51 to 100 (2014-09-05)
	Currency	CHF
	Annual sales	3,900,000,000 (assets, managed 2014-09-05)
		* Document for »About Section«:
		Record changed: 2025-03-16

Advertisement

More documents for Bellevue (Group)

• [1] Pureos Partners AG. (1/17/23). "Press Release: Pureos Partners Welcomes Dr. Ulf Grawunder to Its Team as Venture Partner". Pfäffikon....
• [2] Pureos Partners AG. (9/28/22). "Press Release: Pureos Partners Welcomes Dr. Veronica Gambillara Fonck as New Partner to Its Investment Team". Pfäffikon....
• [3] Tridek-One SAS. (9/15/22). "Press Release: Tridek-One Closes a €16 Million Financing Round to Develop First-in-Class Immune Checkpoint Agonists". Paris....
• [4] Pureos Partners AG. (9/21/21). "Press Release: Pureos Bioventures Expands the Team by the Appointment of Venture Partners". Pfäffikon....
• [5] Araris Biotech AG. (10/22/20). "Press Release: Araris Biotech Completes CHF 15.2 Million Seed Financing Round". Zürich....
• [6] BB Pureos Bioventures. (9/23/20). "Press Release: Pureos Bioventures Closes First Fund with USD 170 Million". St. Peter Port, Guernsey & Küsnacht....
• [7] ImCheck Therapeutics SAS. (9/15/20). "Press Release: ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)". Marseille....
• [8] NovoGo Therapeutics AG. (3/4/19). "Press Release: NovaGo Therapeutics Raises CHF 10 Million to Develop Regenerative Anti-Nogo Therapy for Stroke". Zurich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.